ModifiedArizona Complete HealthPolicy CP.MP.57

Lung Transplantation

Defines medical necessity criteria for lung transplantation for non-Medicare Arizona Complete Health members/enrollees with end-stage chronic lung disease, based on ISHLT 2021 guidance; includes adult and pediatric indications, contraindications, and coding implications.

Policy Summary

PayerArizona Complete Health

PolicyLung Transplantation

Policy CodePolicy CP.MP.57

Change TypeMaterial criteria and coding updates

Effective Date

Next Review Date

Key ActionObtain prior authorization with clinical documentation demonstrating disease-specific thresholds, absence of absolute contraindications, and substance abstinence when applicable.

SourceLink

POLICY UPDATE CHANGES

Updated glomerular filtration rate threshold in contraindication I.C.2. and expanded HIV qualifying criteria in I.C.9.

Clarified active substance use contraindications and documentation of abstinence for ≥ six months prior to transplant.

Added pediatric indication for end-stage emphysema due to alpha-1 antitrypsin deficiency and pediatric-specific criteria mirroring adult disease categories.

Added CPT codes 32850, 32855, 32856 and S2060, S2152 to coding implications.

>50%required 2-year mortality risk

>80%required 5-year survival likelihood

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity and Coverage Criteria

Updated Indications — Interstitial Lung Disease

Policy criteria updated (summary)

Interstitial lung disease criteria update: Adult and pediatric interstitial lung disease criteria were updated to explicitly include end-stage or refractory pulmonary alveolar proteinosis (PAP) as specific indications for transplant listing.N/A

Updates recorded in policy revision; see I.D.1.c.vii.a–b) and I.D.2.c.vii.a–b).

Members with any of the listed absolute contraindications are disqualified from coverage for single-organ lung transplantation unless consideration for multi-organ transplant is explicitly noted. Absolute contraindications include: malignancy with high risk of recurrence or death related to cancer; glomerular filtration rate < 40 mL/min/1.73 m2 (unless considered for multi-organ transplant); acute renal failure on dialysis with low likelihood of recovery; acute liver failure or cirrhosis with portal hypertension or synthetic dysfunction (unless multi-organ transplant); recent stroke, acute coronary syndrome, or myocardial infarction within 30 days; septic shock; active extrapulmonary or disseminated infection; active tuberculosis; uncontrolled HIV (HIV only acceptable when specific criteria are met, see documentation requirements); progressive cognitive impairment; inability to adhere to the regimen necessary to preserve the transplant even with caregiver support; other severe uncontrolled medical conditions expected to limit survival after transplant; and active substance use or dependence without convincing evidence of risk-reduction behaviors (documentation of abstinence for ≥ six months is required when applicable).

This clinical policy defines medical necessity criteria used by Arizona Complete Health for non‑Medicare members seeking lung transplantation; it is a guide to coverage and prior authorization decisions and does not replace the member's coverage documents. Coverage determinations remain subject to the terms, conditions, exclusions and limitations of the member's evidence of coverage, certificate of coverage, policy or contract, and applicable state and federal requirements. Where state Medicaid provisions conflict with this policy, state provisions take precedence.

Lung transplantation is considered not medically necessary when the member fails to meet the policy's required eligibility thresholds or has any absolute contraindication. Key thresholds that must be met include a documented >50% risk of death from lung disease within two years without transplant and a >80% likelihood of five‑year post‑transplant survival from a general medical perspective with adequate graft function. If a member does not meet these mortality or expected‑survival thresholds, or has any of the absolute contraindications listed (see contraindications), the request for transplant will be considered not medically necessary.

Coding and Clinical Thresholds

Covered CPT Codes (procedures referenced)CPTCovered

32850	Donor pneumonectomy(s) (including cold preservation), from cadaver donor.
32851	Lung transplant, single; without cardiopulmonary bypass.
32852	Lung transplant, single; with cardiopulmonary bypass.
32853	Lung transplant, double (bilateral sequential or en bloc); without cardiopulmonary bypass.
32854	Lung transplant, double (bilateral sequential or en bloc); with cardiopulmonary bypass.
32855	Backbench standard preparation of cadaver donor lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare pulmonary venous/atrial cuff, pulmonary artery, and bronchus; unilateral.
32856	Backbench standard preparation of cadaver donor lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare pulmonary venous/atrial cuff, pulmonary artery, and bronchus; bilateral.

HCPCS/Other procedure codes referencedHCPCS

S2060	Lobar lung transplantation.
S2152	Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and post-transplant care in the global definition.

FEV1 thresholds (CF and pediatric)

Adult CF FEV1 thresholdFEV1 < 30% predicted for consideration; alternative tiers include FEV1 < 40% or < 50% predicted with additional qualifying features

Pediatric CF FEV1 thresholdsFEV1 < 30% predicted; alternatively FEV1 < 40% predicted or FEV1 < 50% predicted with any qualifying features (e.g., 6MWD < 400 m, PaCO2 > 50 mmHg, hypoxemia, pulmonary hypertension)

Other adult/pediatric tiersFEV1 < 25% was previously used but updated to FEV1 < 30% in pediatric criteria; document includes higher FEV1 cutoffs (<40%, <50%) when combined with other severity markers

6-Minute Walk Test

6MWT desaturation criterionDesaturation to < 88% during six-minute walk test is a referenced threshold for disease-specific criteria

Prior Authorization, Documentation, and Provider Guidance

Prior Authorization

Prior Authorization Required and Coding

Prior authorization is required for lung transplantation procedures. Providers must obtain prior authorization before scheduling transplant services and submit appropriate clinical documentation to support medical necessity. Reference applicable CPT codes when requesting authorization.

A prior authorization request must include relevant CPT codes (e.g., 32850, 32851, 32852, 32853, 32854, 32855, 32856) and any additional procedural codes used for donor procurement or backbench preparation.
Inclusion of current procedural codes does not guarantee coverage; providers should verify coding against the most up-to-date professional coding sources prior to claim submission.

Prior Authorization

Prior Authorization Guidance

This clinical policy is intended to guide prior authorization decisions. Prior authorization determinations will be made using the medical necessity criteria in this policy along with plan-specific benefit terms.

Use this clinical policy as the clinical guide when preparing prior authorization requests; include documentation that maps the member's clinical status to the policy criteria (e.g., disease-specific thresholds, contraindication assessment, prior therapies tried).

Background and Scope

Lung transplantation is an established therapeutic option for selected patients with end‑stage pulmonary diseases when maximal medical or surgical therapy has failed and a survival benefit is expected. Indications include advanced interstitial lung disease, cystic fibrosis/bronchiectasis, advanced chronic obstructive pulmonary disease, pulmonary vascular diseases, lymphangioleiomyomatosis (LAM) refractory to therapy, primary graft failure, and irreversible acute respiratory distress syndrome with persistent need for mechanical ventilation or extracorporeal support. Selection for single, double, or lobar transplantation depends on disease specifics and patient factors; donor lungs are a limited resource, so candidate selection emphasizes demonstrated high pre‑transplant mortality risk and adequate expected post‑transplant survival.

Definitions and Diagnostic Concepts

Types of lung transplant

Single lung transplantReplacement of one lung; commonly used for certain indications such as COPD and emphysema

Double (bilateral) lung transplantSequential or en bloc replacement of both lungs; commonly indicated for cystic fibrosis, diffuse lung disease, or alpha-1 antitrypsin deficiency

Lobar lung transplantTransplantation of one or more lobes (e.g., lobar transplantation) typically used in size-mismatched donor–recipient scenarios; referenced in coding as S2060

6MWT desaturation

Definition of 6MWT desaturation thresholdDesaturation to < 88% oxygen saturation during the six-minute walk test is used as a disease-specific qualifying threshold

Context of useApplied within interstitial lung disease and cystic fibrosis criteria to demonstrate exercise-induced hypoxemia supporting transplant consideration

Policy Summary

PayerArizona Complete Health

PolicyLung Transplantation

Policy CodePolicy CP.MP.57

Change TypeMaterial criteria and coding updates

Effective Date

Next Review Date

Key ActionObtain prior authorization with clinical documentation demonstrating disease-specific thresholds, absence of absolute contraindications, and substance abstinence when applicable.

SourceLink

On This Page

Glomerular Filtration Rate

GFR contraindication threshold (current policy text)Glomerular filtration rate < 40 mL/min/1.73m2 is listed as an absolute contraindication to single-organ lung transplant unless being considered for multi-organ transplant

Recent revision noteRevision history documents changes between <30 and <40 mL/min/1.73m2 in prior updates; the policy text currently states < 40 mL/min/1.73m2

Multi-organ transplant exceptionGFR below threshold may be acceptable if member is being considered for multi-organ transplant

Denial Risk

Denial Triggers for Transplant Requests

Requests for lung transplant authorization may be denied if the member does not meet all medical necessity criteria or if documentation is insufficient to demonstrate eligibility.

Denial triggers include failure to demonstrate required mortality risk or expected post-transplant survival (e.g., >50% risk of death within two years without transplant and >80% likelihood of five-year post-transplant survival where applicable).
Requests will be denied if any absolute contraindications are present (examples include active, uncontrolled infection, recent myocardial infarction within 30 days, active substance use without evidence of risk-reduction, malignancy with high risk of recurrence, or inadequate renal/hepatic function unless multi-organ transplant is considered).
Lack of required pre-transplant evaluations, incomplete documentation of prior therapies, or absent evidence of abstinence when applicable (e.g., tobacco, alcohol, illicit substances) are common denial reasons.

Denial Risk

Coverage and Denial Considerations

Coverage decisions are subject to the Health Plan's terms and the limitations of coverage documents; administrative or benefit-level exclusions may result in denial even when medical necessity criteria are met.

Even if clinical criteria are satisfied, claims may be denied due to member benefit exclusions, non-covered settings, or lack of network authorization.
The Health Plan retains the right to change, amend, or withdraw this clinical policy and to apply plan-level rules that affect coverage.

Documentation Required

Required Clinical Documentation

Providers must submit complete clinical documentation to support the transplant request. Adequate documentation expedites review and reduces the likelihood of denial.

Required documentation includes: pulmonary function trends (FVC, FEV1, DLCO), six-minute walk test results, right heart catheterization or echocardiography findings for pulmonary hypertension, hospitalization records for respiratory decline or exacerbations, and imaging demonstrating disease progression when applicable.
Documentation of absence of absolute contraindications (e.g., infection workup, malignancy history, renal and hepatic function tests), substance use history and evidence of abstinence when required, and HIV-related documentation (e.g., sustained CD4 >200 cells/mm3, suppressed viral load, effective ART) where applicable.
Evidence of prior maximal medical therapy, including pulmonary rehabilitation participation when appropriate, and prior surgical therapies attempted and their outcomes.

Documentation Required

Documentation Expectations and Provider Responsibility

Providers are expected to exercise professional medical judgment and to supply documentation sufficient for the Health Plan to determine coverage. The policy is not a substitute for clinical judgment.

Coverage determinations rely on the clinical record submitted; incomplete records may delay or result in denial of authorization.
When there is ambiguity, include treating physician rationale, multidisciplinary transplant evaluation notes, and any risk-reduction plans (e.g., substance cessation programs) to support the request.

Prior Authorization

Prior Conservative Therapy Requirement

Prior to considering lung transplantation, maximal conservative therapy must have been tried and documented as ineffective. This includes medical optimization and rehabilitation when applicable.

Document trials of maximal medical therapy relevant to the underlying disease (for example, optimized pharmacologic therapy for pulmonary fibrosis or COPD) and participation in pulmonary rehabilitation when applicable.
Document any prior surgical therapies and their outcomes if relevant to disease progression and transplant candidacy.

End-stage or refractory pulmonary alveolar proteinosis

Newly included ILD indicationEnd-stage or refractory pulmonary alveolar proteinosis (PAP) has been added to adult and pediatric interstitial lung disease criteria as a specific indication for lung transplantation

PAP qualifying conditionsPAP considered when unresponsive to standard therapies (e.g., whole lung lavage, GM-CSF augmentation) or when extensive pulmonary fibrosis develops

Placement in criteriaListed as I.D.1.c.vii.a)-b) for adults and I.D.2.c.vii.a)-b) for pediatrics in the updated policy